Shares of Strongbridge Biopharma (NASDAQ: SBBP) have plummeted premarket on Thursday after the company announced the pricing of its public offering.
Stonebridge said they are offering 11,111,111 ordinary shares to the public at $2.25 per share, wit the company looking to raise $25 million in total from the sale.
The offering is expected to close out on the 21st of September, while underwriters have a 30-day option to purchase up to 1,666,666 of ordinary shares.
Sponsored content
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Strongbridge stated that it will use the money raised from the offering to continue development, facilitate commercial readiness, acquire complementary businesses and commercially launch its drug Recorlev after positive Phase 3 topline data.
One analyst recently commented that Stonebridge’s revenue should significantly increase after the data from the Phase 3 Recorlev study. However, investors don’t seem as enthusiastic.
Strongbridge stock price…
Stonebridge (SBB)/Source: TradingView
Strongbridge shares have plummeted after the news of the pricing of the public offering. Wednesday saw its shares close at $2.80, but they are now trading down at $2.30, after a fall of 17% premarket.
Sam is a trader and lead stock market writer at AskTraders. After starting his career in the forex market, Sam now focuses on stocks, specifically consumer staples.
